Genzyme Buys a Bigger Presence in Oncology
Executive Summary
Two recent acquisition bids by Genzyme stand to suddenly amplify the company's presence in oncology. If the bids go through, the acquisition of Ilex Oncology will bring Genzyme a marketed anti-cancer product, a drug candidate gearing up for Phase II trials and some development capacity. Buying Impath out of bankruptcy will bring Genzyme a diagnostic testing laboratory. Genzyme's managers see no near-term synergies from the firms, but clearly hope eventually to intertwine diagnostics and therapeutics.
You may also be interested in...
Keeping Track of Genzyme
Genzyme is that rare biotech company that is both profitable and diversified. To finance its entrepreneurial businesses without diluting its original shareholders, it has issued separate "tracking" stocks for its various wholly-owned divisions: Tissue Repair, Molecular Oncology, and its General division. The financing strategy brings tax advantages and a way to incentivize managers. But skeptics worry that it adds a complexity that will scare off investors.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.